Ceasing to be a substantial holder

Aug 24, 2026 at 2:43 AM EDT · Issued by Radiopharm Theranostics Limited via ASX

Filed with ASX · Aug 24, 2026 at 2:43 AM EDT

On 6ix: 6ix.com/news/ceasing-to-be-a-substantial-holder-427

To Company Name/Scheme ACN/ARSN 1. Details of substantial holder (1) Name ACN/ARSN (if applicable) - 20/08/2026 The previous notice was given to the company on 17/08/2026 The previous notice was dated 13/08/2026 2. Changes in relevant interests Date of change 3. Changes in...

View Attachment

6ix hasn’t read this filing yet.

Radiopharm Theranostics Limited on 6ix

Earlier from Radiopharm Theranostics

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical TrialAug 20
RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT TrialAug 19
Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain MetastasesAug 17
Change in substantial holdingAug 17
RAD to meet with US FDA to align on RAD 101 Phase 3 TrialAug 16

Later from Radiopharm Theranostics

RAD Doses First Patient in Second Cohort of BetaBart (RV-01)Aug 25
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid TumorsAug 26
Change of Director's Interest Notices x 4Aug 27
Appendix 4E and Preliminary Final ReportAug 28
RAD Announces Positive Data from RAD301 P1 Imaging TrialSep 8

All Radiopharm Theranostics news releases